Ieq Capital LLC purchased a new position in shares of Humana Inc. (NYSE:HUM - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 8,818 shares of the insurance provider's stock, valued at approximately $3,502,000.
Several other institutional investors and hedge funds have also recently modified their holdings of HUM. Callan Family Office LLC acquired a new stake in Humana during the second quarter worth about $538,000. Heartland Advisors Inc. acquired a new stake in shares of Humana during the 2nd quarter worth approximately $11,770,000. Paralel Advisors LLC raised its position in shares of Humana by 31.8% during the 2nd quarter. Paralel Advisors LLC now owns 13,322 shares of the insurance provider's stock valued at $5,292,000 after buying an additional 3,212 shares during the period. Allworth Financial LP purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $699,000. Finally, B. Metzler seel. Sohn & Co. AG acquired a new position in Humana in the second quarter valued at approximately $3,189,000. Institutional investors and hedge funds own 92.38% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the company. Needham & Company LLC assumed coverage on Humana in a research note on Wednesday, May 20th. They set a "buy" rating for the company. Barclays increased their price target on Humana from $344.00 to $407.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on Humana in a research report on Thursday, July 30th. They set a "hold" rating for the company. Robert W. Baird set a $390.00 price objective on shares of Humana in a report on Thursday, July 30th. Finally, Royal Bank Of Canada upped their target price on shares of Humana from $246.00 to $415.00 and gave the company a "sector perform" rating in a research report on Thursday, July 9th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus price target of $403.91.
View Our Latest Report on HUM
Humana Price Performance
HUM stock opened at $386.43 on Tuesday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $46.40 billion, a PE ratio of 36.56, a P/E/G ratio of 2.17 and a beta of 0.72. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $428.88. The business's fifty day moving average price is $383.50 and its 200 day moving average price is $283.61.
Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The company had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.Humana's revenue for the quarter was up 26.2% on a year-over-year basis. During the same period last year, the business posted $6.27 EPS. On average, sell-side analysts anticipate that Humana Inc. will post 9.08 EPS for the current year.
Humana Profile
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Recommended Stories
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
